Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigating Epilepsy: Screening and Evaluation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03478852
Recruitment Status : Recruiting
First Posted : March 27, 2018
Last Update Posted : June 15, 2021
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Neurological Disorders and Stroke (NINDS) )

Brief Summary:

Background:

Epilepsy affects about 1 percent of the U.S. population. Most people with epilepsy respond well to medicine, but some do not. Researchers want people who have diagnosed or suspected epilepsy to participate in ongoing studies. They want to learn more about clinical care for epilepsy. They want fellows and residents to learn more about the care of people with epilepsy.

Objectives:

To learn more about seizures and find ways to best treat people with drug-resistant epilepsy.

Eligibility:

Adults and children ages 8 years and older with diagnosed or suspected epilepsy

Design:

Participants will be screened with:

Physical exam

Medical history

Questionnaires

Participants will have many visits. They may be admitted to the hospital for several weeks. Their medication might be stopped or changed.

Participants will have many tests:

Blood and urine tests

EEG: Wires attached to the head with paste record brain waves. This may be videotaped.

Thinking and memory tests

MRI: Participants lie on a table that slides in and out of a tube. They perform simple tasks in the tube.

MEG: Participants lie on a table and place their head in a helmet to record brain waves.

PET scan: Participants lie on a table that slides into a machine. A small amount of radioactive dye is injected into their arm with an IV. For the IV, a small tube is inserted into the arm with a needle.

Participants will stay enrolled in this study if they join other epilepsy-related studies. They may be contacted at intervals for follow-up. Their participation will end if they have not been seen clinically for their epilepsy for 3 years.


Condition or disease
Seizures Epilepsy Epilepsy, Temporal Lobe Partial Epilepsy

Detailed Description:
Objectives: The primary objective is to maintain a cohort of patients referred to the NIH with a known or suspected diagnosis of epilepsy for eligibility to participate in ongoing protocols. The secondary objectives are to: follow the natural history of subjects with epilepsy and epilepsy-related disorders, and to use data obtained through clinical care for descriptive and/or correlative research. Study Population: Adults and children age 8 years and older referred with a clinical diagnosis of epilepsy Design: Participants In this protocol will be evaluated by study investigators with standard diagnostic clinical studies as clinically indicated to fully characterize their uncontrolled or suspected seizures and related clinical features. There are no study procedures other than data collection for this protocol after screening. Patients will be followed clinically, as needed, to follow the natural history of epilepsy. Follow up will be performed to allow for evaluation of the natural history of drug-resistant epilepsy and its co-morbidities. Outcome Measures: Patients will be screened for eligibility for epilepsy-related research protocols and clinically characterized, including clinical features, imaging, and electrophysiological and neuropsychological characteristics. In addition, standard of care evaluation and treatment will be carried out under this protocol.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Investigating Epilepsy: Screening and Evaluation
Actual Study Start Date : March 28, 2018
Estimated Primary Completion Date : July 30, 2027
Estimated Study Completion Date : July 30, 2027


Group/Cohort
Single Arm
Single arm open enrollment of patients with standard of care treatment and evaluation



Primary Outcome Measures :
  1. Screening and characterization of patients with drug-resistant epilepsy for epilepsy-related protocols [ Time Frame: Ongoing ]
    Patients will be screened for eligibility for epilepsy-related research protocols.


Secondary Outcome Measures :
  1. Teaching and training of clinical fellows and residents [ Time Frame: Ongoing ]
  2. Provision of standard care evaluation and medical management of enrolled patients [ Time Frame: Ongoing ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   8 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adults and children age 8 years and older referred with a known or suspected diagnosis of epilepsy.@@@
Criteria
  • INCLUSION CRITERIA:
  • Age 8 years or older
  • Known or suspected diagnosis of epilepsy
  • Ability to give informed consent or have a legally authorized representative able to give consent (for adults without consent capacity) or parent/guardian able to provide informed consent (for a child)
  • If unable to give informed consent, ability to give assent (for minors 8 and older or adults without consent capacity)

EXCLUSION CRITERIA:

  • Patients with unstable medical conditions that, in the opinion of the investigators, makes participation unsafe, or who, in the opinion of the investigators may be unable to comply with the protocol
  • Patients who are unable to travel to the NIH

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03478852


Contacts
Layout table for location contacts
Contact: Aaliyah H Hamidullah-Thiam (301) 402-7686 aaliyah.hamidullahthiam@nih.gov

Locations
Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010    prpl@cc.nih.gov   
Sponsors and Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
Investigators
Layout table for investigator information
Principal Investigator: Sara K Inati, M.D. National Institute of Neurological Disorders and Stroke (NINDS)
Additional Information:
Layout table for additonal information
Responsible Party: National Institute of Neurological Disorders and Stroke (NINDS)
ClinicalTrials.gov Identifier: NCT03478852    
Other Study ID Numbers: 180066
18-N-0066
First Posted: March 27, 2018    Key Record Dates
Last Update Posted: June 15, 2021
Last Verified: June 8, 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Neurological Disorders and Stroke (NINDS) ):
Seizure Disorder
Seizures
Antiepileptic Drug
Natural History Study
Screening Protocol
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsy
Seizures
Epilepsies, Partial
Epilepsy, Temporal Lobe
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Epileptic Syndromes